Stewart Low serves as Executive Director and board member at the Low Institute for Therapeutics (LIFT) and board member at Gwen Bio. In these roles, Dr. Low directs the preclinical and clinical development of several small molecule drug conjugates in oncology, immunology, and genetic indications.

Prior to his current roles, Dr. Low served as the Chief Operating Officer at Eradivir, Inc. In this role, he was primarily responsible for guiding their lead antiviral asset from early development into a Phase II clinical trial, with oversight of toxicology, CMC, and clinical development.

Dr. Low also co-founded and served as the Chief Scientific Officer at Novosteo Inc., a pharmaceutical company focused on accelerating bone fracture repair, which was successfully acquired by Quince Therapeutics. As the Head of Discovery at Quince Therapeutics, he played a pivotal role on the executive team in developing treatments for bone diseases.

He holds a B.S. in Microbiology from Brigham Young University and a Ph.D. in Bioengineering from the University of Utah. Outside of his professional life, Dr. Low enjoys rock climbing, backpacking, and fly fishing with his children.